Histiocytoma clinical trials
The registry lists 5 studies for Histiocytoma across 8 countries. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2019-12-27. Counting its 2 narrower conditions too, such as Histiocytoma, Malignant Fibrous: 97 studies, 16 open.
Who runs them
Memorial Sloan Kettering Cancer Center (2) · National Center for Research Resources (NCRR) (1) · Celgene (1) · N.N. Petrov National Medical Research Center of Oncology (1)
What is being tested here
Drugs under test in Histiocytoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Albumin-Bound Paclitaxel | 0 | 0 | 1 |
| Paclitaxel | 0 | 0 | 1 |
| Gemcitabine | 0 | 0 | 1 |
| Docetaxel | 0 | 0 | 1 |
| Bevacizumab | 0 | 0 | 1 |
| Pazopanib | 0 | 0 | 1 |
| Dendritic Cell | 0 | 0 | 1 |
Who these studies take
No Histiocytoma study is recruiting now.
Across all 5 studies, recruiting or not: 40% stop at 75 or younger and 20% at 65; 40% take children; 0% are for women only and 0% for men only; 20% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 5 of 5. search them.
- Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid TumorsCompletedNCT01962103Phase 1/27 countries
- Autologous Dendritic Cell Vaccine in Patients With Soft Tissue SarcomaStatus unknownNCT01883518Phase 1/21 country
- Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)TerminatedNCT01418001Phase 1/21 country
- Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma SubtypesCompletedNCT00887809Phase 21 country
- Genetic Study of Patients and Families With Diaphyseal Medullary Stenosis With Malignant Fibrous Histiocytoma of the BoneCompletedNCT000070461 country